Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths
worldwide and is increasing in incidence. Local ablative therapy plays a leading role in HCC …

This review outlines the significance of establishing general rules, a nationwide follow-up
survey, and clinical practice guidelines for liver cancer in Japan. The general rules are an …

Clinical trials are currently ongoing to evaluate the utility of antibodies against programmed
cell death 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte …

Purpose: To retrospectively evaluate the accuracy of a novel software platform for assessing
completeness of percutaneous thermal ablations. Materials & methods: Ninety …

Abstract Objectives Long non‐coding RNAs (lncRNAs) are emerging RNA regulators in
cancer progression, including in hepatocellular carcinoma (HCC). Recently, insufficient …

Residual tumors after insufficient radiofrequency ablation (IRFA) shows accelerated
progression and anti‐PD‐1 resistance. It is also reported that macrophages infiltrating into …

Radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) often leads to
aggressive local recurrence and increased metastasis, and vascular integrity and platelets …

Radiofrequency ablation (RFA) is considered to be a potentially curative therapy for
hepatocellular carcinoma (HCC). However, insufficient RFA (IRFA) can promote rapid …

The multikinase inhibitor sorafenib is the first oral molecular targeted agent with proven
prognostic benefit in unresectable advanced hepatocellular carcinoma (HCC). However, as …

Background: Transarterial chemoembolization (TACE) is recommended for patients with
hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) stage B …